Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to Transform Underperforming Compounds into Next-Gen Cancer Therapies
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Creating Pioneering Pipeline Designed to Transform Cancer, Rare Diseases Treatments
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics’ Commitment to Innovation, Life-Saving Therapies
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
Oncotelic Publishes SITC Meeting 2022 Presentation Materials
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
Oncotelic Announces Formation of Animal Health Division
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.